



**[001360]** In any aspect or embodiment described herein,  $R^{14a}$  and  $R^{14b}$  together with the

carbon atom to which they are attached form , wherein  $R^{23}$  is selected from H,  $C_{1-4}$ alkyl,  $-C(O)C_{1-4}$ alkyl. In any of the aspects or embodiments described herein, the ULM is of the formula:




or a pharmaceutically acceptable salt thereof, wherein  $R_1$ ,  $R_3$ ,  $R_{14a}$ ,  $R_{14b}$ , and  $R_{15}$  of ULM-q and ULM-r are as described herein; and X is CH or N.

**[001361]** In any of the aspects or embodiments described herein,  $R_1$  is  $C_{1-6}$  alkyl.

**[001362]** In any of the aspects or embodiments described herein, one of  $R_{14a}$  and  $R_{14b}$  is H,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl, optionally substituted  $C_{1-4}$  alkylamine,  $C_{1-6}$  alkoxy,  $(CH_2)_qC_{1-6}$  alkoxy,  $(CH_2)_qC_{1-6}$  alkoxy- $C_{3-7}$  heterocycloalkyl,  $(CH_2)_qOH$ ,  $(CH_2)_qNR_{27a}R_{27b}$ ,  $(CH_2)_qNHCOC_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, or  $NR_{27a}R_{27b}$ ; each  $R_{26}$  is independently H,  $C_{1-6}$  alkyl or  $NR_{27a}R_{27b}$ ; each  $R_{27a}$  and  $R_{27b}$  is independently H or  $C_{1-6}$  alkyl; and q is 1, 2, 3 or 4.

**[001363]** In any of the aspects or embodiments described herein, one of  $R_{14a}$  and  $R_{14b}$  is H,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy, optionally substituted  $C_{1-4}$  alkylamine,  $(CH_2)_qC_{1-6}$  alkoxy,  $(CH_2)_qC_{1-6}$  alkoxy- $C_{3-7}$  heterocycloalkyl,  $(CH_2)_qOH$ ,  $(CH_2)_qNR_{27a}R_{27b}$ ,  $(CH_2)_qNHCOC_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, or  $NR_{27a}R_{27b}$ ; each  $R_{26}$  is independently H,  $C_{1-4}$  alkyl or  $NR_{27a}R_{27b}$ ; each  $R_{27a}$  and  $R_{27b}$  is independently H or  $C_{1-4}$  alkyl; and q is 1 or 2.

**[001364]** In any of the aspects or embodiments described herein,  $R_{28}$  is  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl,  $C_{1-6}$  haloalkyl,  $(CH_2)_qOC_{1-6}$ alkyl,  $(CH_2)_qOH$ ,  $(CH_2)_qNR_{27a}R_{27b}$ ,  $(CH_2)_qNHCOC_{1-6}$  alkyl, or




$R_{29}$  is H,  $C_{1-6}$  alkyl,  $NR_{27a}R_{27b}$  or  $(CH_2)_qNHCOC_{1-6}$  alkyl; and wherein q is 1 or 2.

## CLAIMS

### What Is Claimed Is:

1. A compound having the chemical structure:



or a pharmaceutically acceptable salt thereof,

wherein:

- (a) L is  $-(A^L)_q-$ , wherein:


$(A^L)_q$  is a group which is connected to the ULM and the PTM;

q is an integer from 1 to 100;


each  $A^L$  is independently  $CR^{L1}R^{L2}$ , O, S, SO,  $SO_2$ ,  $NR^{L3}$ ,  $SO_2NR^{L3}$ ,  $SONR^{L3}$ ,  $CONR^{L3}$ ,  $NR^{L3}CONR^{L4}$ ,  $NR^{L3}SO_2NR^{L4}$ , CO,  $CR^{L1}=CR^{L2}$ ,  $C\equiv C$ ,  $SiR^{L1}R^{L2}$ ,  $P(O)R^{L1}$ ,  $P(O)OR^{L1}$ ,  $NR^{L3}C(=NCN)NR^{L4}$ ,  $NR^{L3}C(=NCN)$ ,  $NR^{L3}C(=CNO_2)NR^{L4}$ ,  $C_{3-11}$ cycloalkyl optionally substituted with 1-6 groups independently selected from  $R^{L1}$  and  $R^{L2}$ ,  $C_{3-11}$ heterocyclyl optionally substituted with 1-6 groups independently selected from  $R^{L1}$  and  $R^{L2}$ , aryl optionally substituted with 1-6 groups independently selected from  $R^{L1}$  and  $R^{L2}$ , or heteroaryl optionally substituted with 1-6 groups independently selected from  $R^{L1}$  and  $R^{L2}$ , where  $R^{L1}$  or  $R^{L2}$ , each independently are optionally linked to other groups to form cycloalkyl or heterocyclyl moiety, optionally substituted with 1-4  $R^{L5}$  groups; and


$R^{L1}$ ,  $R^{L2}$ ,  $R^{L3}$ ,  $R^{L4}$  and  $R^{L5}$  are, each independently, H, halogen,  $C_{1-8}$ alkyl,  $OC_{1-8}$ alkyl,  $SC_{1-8}$ alkyl,  $NHC_{1-8}$ alkyl,  $N(C_{1-8}alkyl)_2$ ,  $C_{3-11}$ cycloalkyl, aryl, heteroaryl,  $C_{3-11}$ heterocyclyl,  $OC_{3-8}$ cycloalkyl,  $SC_{3-8}$ cycloalkyl,  $NHC_{3-8}$ cycloalkyl,  $N(C_{3-8}cycloalkyl)_2$ ,  $N(C_{3-8}cycloalkyl)(C_{1-8}alkyl)$ , OH,  $NH_2$ , SH,  $SO_2C_{1-8}alkyl$ ,  $CC-C_{1-8}alkyl$ , CCH,  $CH=CH(C_{1-8}alkyl)$ ,  $C(C_{1-8}alkyl)=CH(C_{1-8}alkyl)$ ,  $C(C_{1-8}alkyl)=C(C_{1-8}alkyl)_2$ ,  $COC_{1-8}alkyl$ ,  $CO_2H$ , CN,  $CF_3$ ,  $CHF_2$ ,  $CH_2F$ ,  $NO_2$ ,  $SF_5$ ,  $SO_2NHC_{1-8}alkyl$ ,  $SO_2N(C_{1-8}alkyl)_2$ ,  $SONHC_{1-8}alkyl$ ,  $SON(C_{1-8}alkyl)_2$ ,  $CONHC_{1-8}alkyl$ ,  $CON(C_{1-8}alkyl)_2$ ,  $N(C_{1-8}alkyl)CONH(C_{1-8}alkyl)$ ,  $N(C_{1-8}alkyl)CON(C_{1-8}alkyl)_2$ ,  $NHCONH(C_{1-8}alkyl)$ ,  $NHCON(C_{1-8}alkyl)_2$ ,  $NHCONH_2$ ,  $N(C_{1-8}alkyl)SO_2NH(C_{1-8}alkyl)$ ,  $N(C_{1-8}alkyl)SO_2N(C_{1-8}alkyl)_2$ ,  $NH SO_2NH(C_{1-8}alkyl)$ ,  $NH SO_2N(C_{1-8}alkyl)_2$ , or  $NH SO_2NH_2$ ;

- (b) the ULM is:



wherein:

W<sup>3</sup> is optionally substituted aryl, optionally substituted heteroaryl, or  ;  
R<sub>9</sub> and R<sub>10</sub> are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl, or R<sub>9</sub>, R<sub>10</sub>, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;  
R<sub>11</sub> is optionally substituted heterocyclyl, optionally substituted alkoxy, optionally



R<sub>12</sub> is H or optionally substituted alkyl;

R<sub>13</sub> is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;

one of R<sub>14a</sub> and R<sub>14b</sub> is H, amino, haloalkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamino, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR<sub>26</sub>, CONR<sub>27a</sub>R<sub>27b</sub>, NHCOR<sub>26</sub>, or NHCH<sub>3</sub>COR<sub>26</sub>; and the other of R<sub>14a</sub> and R<sub>14b</sub> is H; or R<sub>14a</sub> and R<sub>14b</sub> together with the carbon atom to which they are attached form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl, or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxy or aziridinyl;

W<sup>5</sup> is optionally substituted phenyl, optionally substituted naphthyl, or an optionally substituted 5-10 membered heteroaryl;

R<sub>15</sub> is H, halogen, CN, OH, NO<sub>2</sub>, NR<sub>27a</sub>R<sub>27b</sub>, OR<sub>27a</sub>, CONR<sub>27a</sub>R<sub>27b</sub>, NR<sub>27a</sub>COR<sub>27b</sub>, SO<sub>2</sub>NR<sub>27a</sub>R<sub>27b</sub>, NR<sub>27a</sub>SO<sub>2</sub>R<sub>27b</sub>, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;

each R<sub>16</sub> is independently halogen, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;

o is 0, 1, 2, 3, or 4;

each R<sub>18</sub> is independently H, halogen, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, or haloalkoxy;


each R<sub>26</sub> is independently H, optionally substituted alkyl, or NR<sub>27a</sub>R<sub>27b</sub>;

each R<sub>27a</sub> and R<sub>27b</sub> is independently H, optionally substituted alkyl, or R<sub>27a</sub> and R<sub>27b</sub> together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;

p is 0, 1, 2, 3, or 4; and

----- indicates the site of attachment of L; and

(c) the PTM is:



wherein:


 is the attachment point to L;

$W_{PTM1}$  is a phenyl substituted with a hydroxy substituent and optionally substituted with 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, and cyano;

$W_{PTM2}$  is pyridazinyl optionally substituted with an amino group;

$W_{PTM3}$  is an optionally substituted 5–6-membered heteroaryl, an optionally substituted 4-9 cycloalkyl, an optionally substituted 4-9 membered heterocyclyl, an optionally substituted bridged bicycloalkyl, or an optionally substituted bridged biheterocyclyl, preferably an optionally substituted pyrazole, pyrrole, imidazole, oxazole, oxadiazole, or triazole;

$W_{PTM5}$  is an optionally substituted 5–6-membered aryl or an optionally substituted 5–6-membered heteroaryl; or




wherein:

 is the attachment point to L;


$W_{PTM1}$  is a phenyl substituted with a hydroxy substituent and optionally substituted with 1 or 2 substituents independently selected from hydroxy, halogen, alkoxy, alkyl, haloalkyl, amino, phosphate, alkylamino, and cyano;

$W_{PTM2}$  is a pyridazinyl substituted with an amino group; and

$W_{PTM6}$  and  $W_{PTM7}$  are a spirocyclic ring system with a structure selected from:




2. The compound according to claim 1, wherein the PTM is:




3. The compound according to claim 2, wherein  $W_{PTM3}$  is an optionally substituted pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, oxadiazolyl, or triazolyl.

4. The compound according to claim 2, wherein the PTM is:




5. The compound according to claim 4, wherein the PTM is:




wherein  $W_{PTM5}$  is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl.


6. The compound according to claim 1, wherein the PTM is:




7. The compound according to claim 1, wherein the PTM is:




8. The compound according to claim 1, wherein the PTM is:





9. The compound according to claim 1, wherein the ULM is:



wherein:

$R_1$  is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl;

$R_{14a}$  is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, or isopropyl;

$R_{15}$  is H, halogen, CN, OH, NO<sub>2</sub>, optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl, or optionally substituted heterocyclyl;


X is CH<sub>2</sub> or C=O;

$R_3$  is an optionally substituted 5- or 6-membered heteroaryl; and



indicates the site of attachment of the chemical linker group.

10. The compound according to claim 1, wherein the ULM is:




or a pharmaceutically acceptable salt thereof, wherein:

$R_1$  is H, optionally substituted alkyl, or optionally substituted cycloalkyl;

$R_3$  is optionally substituted 5- or 6-membered heteroaryl;

W<sup>5</sup> is optionally substituted phenyl, optionally substituted naphthyl, or optionally substituted pyridinyl;

one of R<sub>14a</sub> or R<sub>14b</sub> is H, optionally substituted alkyl, haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamino, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl, COR<sub>26</sub>, CONR<sub>27a</sub>R<sub>27b</sub>, NHCOR<sub>26</sub>, or NHCH<sub>3</sub>COR<sub>26</sub>; and the other of R<sub>14a</sub> or R<sub>14b</sub> is H; or R<sub>14a</sub> and R<sub>14b</sub>, together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxy or aziridinyl;




each R<sub>16</sub> is independently halogen, CN, optionally substituted alkyl, optionally substituted haloalkyl, hydroxy, or haloalkoxy;



each R<sub>26</sub> is independently H, optionally substituted alkyl, or NR<sub>27a</sub>R<sub>27b</sub>;

each R<sub>27a</sub> and R<sub>27b</sub> is independently H, optionally substituted alkyl, or R<sub>27a</sub> and R<sub>27b</sub> together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;


R<sub>28</sub> is H, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted alkylamino, optionally substituted hydroxyalkyl, amino, optionally substituted alkynyl, or optionally substituted cycloalkyl;

o is 0, 1, or 2; and



11. The compound according to claim 10, wherein R<sub>15</sub> is  or , wherein R<sub>28a</sub> is halogen, optionally substituted alkyl, or fluoroalkyl.

12. The compound according to claim 1, wherein the ULM is :



wherein:





$R_3$  is an optionally substituted 5- or 6-membered heteroaryl;

each of  $X^4$ ,  $X^5$ , and  $X^6$  is CH or N, wherein no more than 2 are N;


$R^1$  is  $C_{1-6}$  alkyl;

one of  $R^{14a}$  or  $R^{14b}$  is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, optionally substituted alkylamino, optionally substituted heteroalkyl, optionally substituted alkyl-heterocycloalkyl, optionally substituted alkoxy-heterocycloalkyl,  $COR^{26}$ ,  $CONR^{27a}R^{27b}$ ,  $NHCOR^{26}$ , or  $NHCH_3COR^{26}$ ; and the other of  $R^{14a}$  or  $R^{14b}$  is H; or  $R^{14a}$  and  $R^{14b}$ , together with the carbon atom to which they are attached, form an optionally substituted 3 to 5 membered cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocyclyl, wherein the spiroheterocyclyl is not epoxy or aziridinyl;

each  $R^{27a}$  and  $R^{27b}$  is independently H or  $C_{1-6}$  alkyl;

$R^{15}$  is, , , , , or CN;

$R^{28}$  is H, methyl,  $CH_2N(Me)_2$ ,  $CH_2OH$ ,  $CH_2O(C_{1-4}alkyl)$ ,  $CH_2NHC(O)C_{1-4}alkyl$ ,  $NH_2$ ,



$R^{28C}$  is H, methyl, fluoro, or chloro;

$R^{16}$  is H,  $C_{1-4}$  alkyl, fluoro, chloro, CN, or  $C_{1-4}alkoxy$ ; and



indicates the site of attachment of the chemical linker group.

13. The compound according to claim 12, wherein:


one of  $R^{14a}$  or  $R^{14b}$  is H,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  hydroxyalkyl,  $C_{1-4}$  alkyloxyalkyl,  $C_{1-4}$  alkyl- $NR_{27a}R_{27b}$  and  $CONR_{27a}R_{27b}$ ; and the other of  $R^{14a}$  or  $R^{14b}$  is H; or

$R^{14a}$  and  $R^{14b}$ , together with the carbon atom to which they are attached form a  $C_{3-4}$  cycloalkyl.

14. The compound according to claim 12 or 13, wherein  $R^{14a}$  and  $R^{14b}$  together with

the carbon atom to which they are attached, form , wherein  $R^{23}$  is selected from H,  $C_{1-4}$ alkyl, and  $-C(O)C_{1-4}$ alkyl.

15. The compound according to claim 12, wherein the ULM is:



wherein:

$X^4$  is CH or N, and



indicates the site of attachment of the chemical linker group.


16. The compound according to claim 1, wherein  $R_1$  is  $C_{1-6}$  alkyl.

17. The compound according to any one of claims 12, 15, or 16, wherein:

one of  $R_{14a}$  or  $R_{14b}$  is H,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl, optionally substitute  $C_{1-4}$  alkylamino,  $C_{1-6}$  alkoxy,  $(CH_2)_qC_{1-6}$  alkoxy,  $(CH_2)_qC_{1-6}$  alkoxy- $C_{3-7}$  heterocycloalkyl,  $(CH_2)_qOH$ ,  $(CH_2)_qNR_{27a}R_{27b}$ , or  $(CH_2)_qNHCOC_{1-6}$  alkyl; and the other of  $R^{14a}$  or  $R^{14b}$  is H; or  $R^{14a}$  and  $R^{14b}$ , together with the carbon atom to which they are attached form  $C_{3-5}$  cycloalkyl;

each  $R_{26}$  is independently H,  $C_{1-6}$  alkyl, or  $NR_{27a}R_{27b}$ ;  
each  $R_{27a}$  and  $R_{27b}$  is independently H or  $C_{1-6}$  alkyl; and  
q of the ULM is 1, 2, 3, or 4.


18. The compound according to any one of claims 12, 15, or 16, wherein:  
one of  $R_{14a}$  or  $R_{14b}$  is H,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy, optionally substituted  $C_{1-4}$  alkylamino,  $(CH_2)_qC_{1-6}$  alkoxy,  $(CH_2)_qC_{1-6}$  alkoxy- $C_{3-7}$  heterocycloalkyl,  $(CH_2)_qOH$ ,  $(CH_2)_qNR_{27a}R_{27b}$ , or  $(CH_2)_qNHCOC_{1-6}$  alkyl; and the other of  $R^{14a}$  or  $R^{14b}$  is H;  $R^{14a}$  and  $R^{14b}$ , together with the carbon atom to which they are attached form  $C_{3-5}$  cycloalkyl;  
each  $R_{26}$  is independently H,  $C_{1-4}$  alkyl or  $NR_{27a}R_{27b}$ ;  
each  $R_{27a}$  and  $R_{27b}$  is independently H or  $C_{1-4}$  alkyl; and  
q of the ULM is 1 or 2.

19. The compound according to claim 10, wherein:  
 $R_{28}$  is  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl,  $C_{1-6}$  haloalkyl,  $(CH_2)_qOC_{1-6}$  alkyl,  $(CH_2)_qOH$ ,  $(CH_2)_qNR_{27a}R_{27b}$ ,  
 $(CH_2)_qNHCOC_{1-6}$  alkyl, or   $R_{29}$ ;  
 $R_{29}$  is H,  $C_{1-6}$  alkyl,  $NR_{27a}R_{27b}$  or  $(CH_2)_qNHCOC_{1-6}$  alkyl; and  
q of the ULM is 1 or 2.

20. The compound according to claim 12, wherein  $R^3$  is isoxazolyl, 4-chloroisoxazolyl, 4-fluoroisoxazolyl, or pyrazolyl.

21. The compound according to claim 20, wherein  $X^4$  is CH.

22. The compound according to claim 1, wherein the ULM is:



wherein:


$R^1$  is  $C_{1-6}$  alkyl;

$X^4$  is CH or N;

$R_{30}$  is H, F, or Cl;


$R^{16}$  is H,  $C_{1-4}$ alkyl, fluoro, chloro, CN, or  $C_{1-4}$ alkoxy;

$R_{28}$  is H, methyl,  $CH_2N(Me)_2$ ,  $CH_2OH$ ,  $CH_2O(C_{1-4}alkyl)$ ,  $CH_2NHC(O)C_{1-4}alkyl$ ,  $NH_2$ ,









indicates the site of attachment of L.


23. The compound according to claim 22, wherein the ULM is:





24. The compound according to claim 1, wherein the ULM is:


















































,




,




,




,




,




,




,




,




,






,







,











,











































































wherein  indicates the site of attachment of L.

25. The compound according to any one of claims 1 to 24, wherein L is:



wherin:

$W^{L1}$  and  $W^{L2}$  are each independently aryl, heteroaryl, cyclic, heterocyclyl,  $C_{1-6}$  alkyl, bicyclic, biaryl, biheteroaryl, or biheterocyclyl, each optionally substituted with  $R^Q$ , each  $R^Q$  is independently a H, halo, OH, CN,  $CF_3$ , hydroxyl, nitro,  $C\equiv CH$ ,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, optionally substituted linear or branched  $C_1-C_6$  alkyl, optionally substituted linear or branched  $C_1-C_6$  alkoxy, optionally substituted linear or branched  $OC_{1-3}$ alkyl, OH,  $NH_2$ ,  $NR^{Y1}R^{Y2}$ , CN;

or 2  $R^Q$  groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;

$Y^{L1}$  is each independently a bond,  $NR^{YL1}$ , O, S,  $NR^{YL2}$ ,  $CR^{YL1}R^{YL2}$ , C=O, C=S, SO,  $SO_2$ , optionally substituted linear or branched  $C_1-C_6$  alkyl and optionally one or more C atoms are replaced with O, or optionally substituted linear or branched  $C_1-C_6$  alkoxy;

$Q^L$  is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 1-6  $R^Q$ , each  $R^Q$  is independently H, optionally substituted linear or branched  $C_{1-6}$  alkyl optionally substituted by 1 or more halo or  $C_{1-6}$  alkoxyl;

or 2  $R^Q$  groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;

$R^{YL1}$ ,  $R^{YL2}$  are each independently H, OH, optionally substituted linear or branched  $C_{1-6}$  alkyl optionally substituted by 1 or more halogen or  $C_{1-6}$  alkoxyl;

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and






26. The compound according to any one of claims 1 to 24, wherein the L is selected from:
































27. The compound according to any one of claims 1 to 24, wherein the L is selected from:




Cc1nc(C)cc(C1CCC2C1C2)c1ccc(cc1)CN[C@@H](C(C)(C)C)C(=O)N2CCC(O)C2=O









,




,




,









,














,















,


































































































































































































































































































































































,




,




,




,




,




,




,




,




,







,




,




,







,




,




,




,




,







,









,











,





























,




,




,




,




,








,








,




,









,




,







,











,












,

















































,







,











,











,























9




9



9



9



29. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.

30. The pharmaceutical composition according to claim 29, wherein the composition further comprises an additional bioactive agent.

31. The pharmaceutical composition according to claim 30, wherein the additional bioactive agent is anti-cancer agent.

32. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 for use in treating cancer.

33. The pharmaceutical composition according to claim 32, wherein the cancer is a SWI/SNF associated cancer or a cancer with a SMARCA4 mutation.

34. The pharmaceutical composition according to claim 33, wherein the SWI/SNF associated cancer or the cancer with a SMARCA4 mutation is lung cancer or non-small cell lung cancer.

35. The pharmaceutical composition according to claim 32, wherein the cancer is a SMARCA4-deficient cancer or a cancer with decreased expression of SMARCA4 relative to normal SMARCA4 expression.

36. The pharmaceutical composition according to claim 35, wherein the SMARCA4-deficient cancer or the cancer with decreased expression of SMARCA4 relative to normal SMARCA4 expression is lung cancer or non-small cell lung cancer.